Reliability of adult retrospective recall of lifetime tobacco use

Brigham, Janet; Lessov‐Schlaggar, Christina N.; Javitz, Harold S.; McElroy, Mary; Krasnow, Ruth E.; Swan, Gary E.

doi:10.1080/14622200701825718

Cited by 59 publications

(67 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In large samples, the ICC has an F distribution, which was used to derive asymptotic 95% CI estimates. Following Brigham et al (2008Brigham et al ( , 2009, indices of reliability ranging from .70 to 1.0 were considered high, .50-.69 were considered moderate, .30-.49 were considered modest, and <.30 were considered low. Other interpretive guidelines exist, however; for example, Landis and Koch (1977) rated k as .80-1.0 = almost perfect, .60-.80 = substantial, .40-.60 = moderate, .20-.40 = fair, .00-.20 = slight, and <.00 = poor.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, it is important to establish the reliability of smoking history indices collected retrospectively. The most pertinent research addressing these issues has been conducted by Brigham et al (Brigham et al, 2008, 2010, developers of the Lifetime Tobacco Use Questionnaire (LTUQ), a web-based retrospective assessment. Their first two studies evaluated test-retest reliability of self-administered web-based LTUQ variables across 2-year and 2-month intervals in adult samples of convenience, respectively (Brigham et al, 2008(Brigham et al, , 2009).…”

Section: Introductionmentioning

confidence: 99%

“…The most pertinent research addressing these issues has been conducted by Brigham et al (Brigham et al, 2008, 2010, developers of the Lifetime Tobacco Use Questionnaire (LTUQ), a web-based retrospective assessment. Their first two studies evaluated test-retest reliability of self-administered web-based LTUQ variables across 2-year and 2-month intervals in adult samples of convenience, respectively (Brigham et al, 2008(Brigham et al, , 2009). In the third study, smoking data collected in two separate prospective cohort studies were used to test the validity of retrospective LTUQ data collected 3.9 years later in one sample and 19.5 years later in the other (Brigham et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Development and Reliability of the Lifetime Interview on Smoking Trajectories

Colby

Clark

Rogers

et al. 2011

Nicotine & Tobacco Research

View full text Add to dashboard Cite

Conclusions:Although retrospective reports have unavoidable limitations, our findings indicate that the LIST is a reliable instrument for assessing detailed retrospective smoking history data and can be used to add to the knowledge base of how patterns of use relate to a variety of outcomes of interest. IntroductionRetrospective assessment of lifetime history of health risk behaviors and related disorders is widely used, especially in transdisciplinary research of how intra-individual and contextual factors interact over time (Abrams, Leslie, Mermelstein, Kobus, & Clayton, 2003). In the specific case of tobacco use, retrospective life history data are important for studies of the natural history of tobacco use and nicotine dependence (Brigham et al., 2010), the temporal patterning of tobacco use with co-occurring risk behaviors and morbidities over time (Bernstein, Zvolensky, Schmidt, & Sachs-Ericcson, 2007;Kahler et al., 2008), and research on the prevalence, contexts, and correlates of tobacco and other substance use disorders (cf., Degenhardt et al., 2008). Specific aspects of tobacco use history, such as age of onset and subjective reactions to early smoking experiences, have been studied as predictors of smoking severity and in identifying high-risk phenotypes (Johnson & Schultz, 2005). In contrast, indices reflecting total lifetime exposure to smoking (e.g., "pack-years"; usually defined as the total number of years one smoked multiplied by cigarette packs smoked per day) are Abstract Introduction: Assessments of lifetime smoking history are useful in many types of research including surveillance, epidemiology, prevention, intervention, and studies of genetic phenotypes and heritability. Because prospective assessment is impractical for most research, our objective was to develop a reliable retrospective measure of lifetime smoking history. This paper presents descriptive and test-retest reliability data on smoking history variables assessed using the Lifetime Interview on Smoking Trajectories (LIST).Methods: Data were collected on a birth cohort sample of 1,625 men and women (ages 34-44) from the Collaborative Perinatal Project. A subsample of 344 was invited to participate in a retest interview 4-8 weeks later and 220 participated. Indices of test-retest reliability were evaluated for smoking history variables, including: (a) early smoking experiences; (b) age at various smoking milestones, such as first puff, and progression to weekly and daily smoking; (c) smoking rate and time to first cigarette within initial, current, most recent, and heaviest phases; and (d) prolonged nonsmoking phases. Results:Responses to whether each of 5 major smoking milestones occurred were all highly reliable (k = .78-.92), and of the 20 phase-specific variables assessed, more than half were reported at the highest level of reliability. None of the variables demonstrated low reliability.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development and Reliability of the Lifetime Interview on Smoking Trajectories

Colby

Clark

Rogers

et al. 2011

Nicotine & Tobacco Research

View full text Add to dashboard Cite

show abstract

“…Smoking status-Smoking status was collected using a smoking calendar whereby, at each contact, participants reported on their smoking each day since the last contact using time-line follow-back (Brigham et al, 2008;Sobell, Sobell, Leo, & Cancilla, 1988 …”

Section: Methods Participantsmentioning

confidence: 99%

“…There were no statistically significant differences between the active and placebo treatment groups on age, cigarettes smoked per day, FTND score, baseline CO level, gender, marital status, race, Hispanic origin, or education. Consistent with the FDA package instructions, participants on nicotine replacement products such as lozenge and patch were instructed not to smoke while using nicotine replacement therapy (e.g., to remove the nicotine patch before smoking a cigarette).Smoking status-Smoking status was collected using a smoking calendar whereby, at each contact, participants reported on their smoking each day since the last contact using time-line follow-back (Brigham et al, 2008;Sobell, Sobell, Leo, & Cancilla, 1988 …”

mentioning

confidence: 99%

The effect of five smoking cessation pharmacotherapies on smoking cessation milestones.

Japuntich¹,

Piper²,

Leventhal³

et al. 2014

Translational Issues in Psychological Science

View full text Add to dashboard Cite

Objective-Most smoking cessation studies use long-term abstinence as their primary outcome measure. Recent research suggests that long-term abstinence may be an insensitive index of important smoking cessation mechanisms. The goal of the current study is to examine the effects of five smoking cessation pharmacotherapies using Shiffman et al. 's (2006) approach of examining the effect of smoking cessation medications on three process markers of cessation or smoking cessation "milestones": initial abstinence, lapse, and the lapse-relapse transition.Method-The current study (N = 1504, 58% female, 84% Caucasian) examines the effect of five smoking cessation pharmacotherapy treatments vs. placebo (bupropion, nicotine lozenge, nicotine patch, bupropion + lozenge, patch + lozenge) on Shiffman et al.'s smoking cessation milestones over 8 weeks following a quit attempt. Results-Resultsshow that all five medication conditions decreased rates of failure to achieve initial abstinence and most (with the exception of the nicotine lozenge) decreased lapse risk, however only the nicotine patch and bupropion + lozenge conditions affected the lapse-relapse transition.Conclusions-These findings demonstrate that medications are effective at aiding initial abstinence and decreasing lapse risk, but generally do not decrease relapse risk following a lapse. The analysis of cessation milestones sheds light on important impediments to long-term smoking abstinence, suggests potential mechanisms of action of smoking cessation pharmacotherapies, and identifies targets for future treatment development.Much smoking cessation research has used long-term abstinence to evaluate the efficacy of cessation treatments. Recently, Shiffman and colleagues (2006) introduced the notion that successful cessation may be viewed as being dependent upon several component events that Corresponding Author: Sandra Japuntich, Ph.D., Mongan Institute for Health Policy, Massachusetts General Hospital, 50 Staniford St., 9 th Fl., Boston, MA, 02114, (617) 726-7886, sjapuntich@partners.org. The authors are solely responsible for the analyses, content, and writing of this article. The authors have full control of all primary data, and they agree to allow the journal to review the data if requested.We declare that this research complies with the current laws of the United States of America. All participants gave written informed consent, and the study was approved by the Institutional Review Board. NIH Public AccessAuthor Manuscript J Consult Clin Psychol. Author manuscript; available in PMC 2011 March 16. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript they term "milestones." These include: ability to stop smoking (achieve short-term abstinence), avoid a lapse (smoking on a single day), and if a lapse occurs, avoid a relapse (a return to daily smoking; Shiffman et al., 2006). Parsing the multicomponential process of smoking cessation into meaningful subunits may provide insight into the process of cessation and relapse, and provide ...

show abstract

A Randomized Placebo-Controlled Clinical Trial of 5 Smoking Cessation Pharmacotherapies

Piper

Smith²,

Schlam³

et al. 2009

Arch Gen Psychiatry

221

241

View full text Add to dashboard Cite

Context Little direct evidence exists on the relative efficacies of different smoking cessation pharmacotherapies, yet such evidence is needed to make informed decisions about their clinical use. Objective The primary objective of this research was to assess the relative efficacies of five smoking cessation pharmacotherapy interventions using placebo-controlled, head-to-head comparisons. Design This was a randomized double-blind, placebo-controlled clinical trial. Setting Smokers were recruited from the community at two urban research sites. Patients Participants were 1504 adult smokers who smoked at least 10 cigarettes per day during the past 6 months and reported being motivated to quit smoking. Participants were excluded if they reported: using any form of tobacco other than cigarettes; current use of bupropion; having a current psychosis or schizophrenia diagnosis; or having medical contraindications for any of the study medications. Interventions Participants were randomized to one of six treatment conditions: nicotine lozenge, nicotine patch, bupropion SR, nicotine patch + nicotine lozenge, bupropion + nicotine lozenge or placebo. In addition, all participants received six individual counseling sessions. Main Outcome Measures The main outcome measures were biochemically-confirmed 7-day point-prevalence abstinence assessed at 1 week post-quit, end of treatment (8 weeks post-quit) and 6 months post-quit. Other outcomes were initial cessation, number of days to lapse, number of days to relapse, and latency to relapse after the first lapse. Results All pharmacotherapies differed from placebo when examined without protection for multiple comparisons (OR’s = 1.63–2.34). With such protection, only the nicotine patch + nicotine lozenge (OR = 2.34, p < .001) produced significantly higher abstinence rates at 6-months post-quit than did placebo. Conclusions While the nicotine lozenge, bupropion, and bupropion + lozenge produced effects that were comparable to those reported in previous research, the nicotine patch + lozenge produced the greatest benefit relative to placebo for smoking cessation.

show abstract

Reliability of adult retrospective recall of lifetime tobacco use

Cited by 59 publications

References 0 publications

Development and Reliability of the Lifetime Interview on Smoking Trajectories

Development and Reliability of the Lifetime Interview on Smoking Trajectories

The effect of five smoking cessation pharmacotherapies on smoking cessation milestones.

A Randomized Placebo-Controlled Clinical Trial of 5 Smoking Cessation Pharmacotherapies

Contact Info

Product

Resources

About